[1]
|
Nagtegaal, I.D., Odze, R.D., Klimstra, D., et al. (2020) The 2019 WHO Classification of Tumours of the Digestive Sys-tem. Histopathology, 76, 182-188. https://doi.org/10.1111/his.13975
|
[2]
|
Pavel, M., Oberg, K., Falconi, M., et al. (2020) Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 844-860.
https://doi.org/10.1016/j.annonc.2020.03.304
|
[3]
|
Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA On-cology, 3, 1335-1342.
https://doi.org/10.1001/jamaoncol.2017.0589
|
[4]
|
Cives, M. and Strosberg, J.R. (2018) Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians, 68, 471-487. https://doi.org/10.3322/caac.21493
|
[5]
|
Shah, M.H., Goldner, W.S., Benson, A.B., et al. (2021) Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Com-prehensive Cancer Network, 19, 839-868.
https://doi.org/10.6004/jnccn.2021.0032
|
[6]
|
Sunami, K., Ichikawa, H., Kubo, T., et al. (2019) Feasibility and Util-ity of a Panel Testing for 114 Cancer-Associated Genes in a Clinical Setting: A Hospital-Based Study. Cancer Science, 110, 1480-1490.
https://doi.org/10.1111/cas.13969
|
[7]
|
Stang, A., Wellmann, I., Holleczek, B., et al. (2022) Incidence and Relative Survival of Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Neoplasms in Germany, 2009-2018. An In-Depth Analysis of Two Population-Based Cancer Registries. Cancer Epidemiology, 79, Article ID: 102204. https://doi.org/10.1016/j.canep.2022.102204
|
[8]
|
Chang, J.S., Chen, L.T., Shan, Y.S., et al. (2021) An Updated Analysis of the Epidemiologic Trends of Neuroendocrine Tumors in Taiwan. Scientific Reports, 11, Article No. 7881. https://doi.org/10.1038/s41598-021-86839-2
|
[9]
|
Koizumi, T., Otsuki, K., Tanaka, Y., et al. (2022) Epidemiology of Neuroendocrine Neoplasmas in Japan: Based on Analysis of Hospital-Based Cancer Registry Data, 2009-2015. BMC Endocrine Disorders, 22, Article No. 105.
https://doi.org/10.1186/s12902-022-01016-4
|
[10]
|
Fu, M., Yu, L., Yang, L., et al. (2022) Gender Differences in Pancreatic Neuroendocrine Neoplasms: A Retrospective Study Based on the Population of Hubei Province, China. Fron-tiers in Endocrinology (Lausanne), 13, Article ID: 885895. https://doi.org/10.3389/fendo.2022.885895
|
[11]
|
李浩明, 曲玉清, 王先令, 等. 286例功能性胰腺神经内分泌肿瘤的临床特点及治疗: 一项单中心回顾性研究[J]. 国际内分泌代谢杂志, 2021, 41(3): 178-183.
|
[12]
|
Fraenkel, M., Faggiano, A. and Valk, G.D. (2015) Epidemiology of Neuroendocrine Tumors. Frontiers of Hormone Research, 44, 1-23. https://doi.org/10.1159/000381970
|
[13]
|
Janson, E.T., Knigge, U., Dam, G., et al. (2021) Nordic Guidelines 2021 for Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms. Acta Oncologica, 60, 931-941.
https://doi.org/10.1080/0284186X.2021.1921262
|
[14]
|
Mafficini, A. and Scarpa, A. (2019) Genetics and Epigenet-ics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine Reviews, 40, 506-536. https://doi.org/10.1210/er.2018-00160
|
[15]
|
Venizelos, A., Elvebakken, H., Perren, A., et al. (2021) The Molecular Characteristics of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine-Related Cancer, 29, 1-14. https://doi.org/10.1530/ERC-21-0152
|
[16]
|
Obazee, O., Capurso, G., Tavano, F., et al. (2018) Common Genetic Variants Associated with Pancreatic Adenocarcinoma May Also Modify Risk of Pancreatic Neuroendocrine Neoplasms. Carcinogenesis, 39, 360-367.
https://doi.org/10.1093/carcin/bgx150
|
[17]
|
Pulvirenti, A., Rao, D., Mcintyre, C.A., et al. (2019) Limited Role of Chromogranin A as Clinical Biomarker for Pancreatic Neuroendocrine Tumors. HPB (Oxford), 21, 612-618. https://doi.org/10.1016/j.hpb.2018.09.016
|
[18]
|
Di Giacinto, P., Rota, F., Rizza, L., et al. (2018) Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology, 2018, Article ID: 8126087.
https://doi.org/10.1155/2018/8126087
|
[19]
|
Lyubimova, N.V., Timofeev, Y.S., Markovich, A.A., et al. (2022) Chromogranin B in Blood Serum of Patients with Neuroendocrine Tumors. Kliniceskaja Laboratornaja Diagnostika, 67, 440-443.
https://doi.org/10.51620/0869-2084-2022-67-8-440-443
|
[20]
|
Takase, Y., Naito, Y., Okabe, Y., et al. (2019) Insu-linoma-Associated Protein 1 Expression in Pancreatic Neuroendocrine Tumours in Endoscopic Ultrasound-Guided Fi-ne-Needle Aspiration Cytology: An Analysis of 14 Patients. Cytopathology, 30, 194-200. https://doi.org/10.1111/cyt.12640
|
[21]
|
Baykara, Y., Xiao, Y., Yang, D.F., et al. (2022) Utility of Secretagogin as a Marker for the Diagnosis of Lung Neuroendocrine Carcinoma. Virchows Archiv, 481, 31-39. https://doi.org/10.1007/s00428-022-03312-9
|
[22]
|
Wu, X.Y., Hu, Y.B., Li, H.J., et al. (2018) Diagnostic and Therapeutic Value of Progastrin-Releasing Peptide on Small-Cell Lung Cancer: A Single-Center Experience in China. Journal of Cellular and Molecular Medicine, 22, 4328-4334. https://doi.org/10.1111/jcmm.13722
|
[23]
|
Korse, C.M., Taal, B.G., Vincent, A., et al. (2012) Choice of Tumour Markers in Patients with Neuroendocrine Tumours Is Dependent on the Histological Grade. A Marker Study of Chromogranin A, Neuron Specific Enolase, Progastrin-Releasing Peptide and Cytokeratin Fragments. European Journal of Cancer, 48, 662-671.
https://doi.org/10.1016/j.ejca.2011.08.012
|
[24]
|
Hofland, J., Zandee, W.T. and De Herder, W.W. (2018) Role of Biomarker Tests for Diagnosis of Neuroendocrine Tumours. Nature Reviews Endocrinology, 14, 656-669. https://doi.org/10.1038/s41574-018-0082-5
|
[25]
|
Nobels, F.R., Kwekkeboom, D.J., Coopmans, W., et al. (1997) Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the Alpha-Subunit of Glycoprotein Hormones. The Journal of Clinical Endocrinology & Metabolism, 82, 2622-2628. https://doi.org/10.1210/jc.82.8.2622
|
[26]
|
Wang, X.L., Wang, L.X., Ding, B.Q., et al. (2022) Expression and Clinicopathological Significance of SOX11 in Small-Cell Lung Cancer. BioMed Research International, 2022, Article ID: 1707914.
https://doi.org/10.1155/2022/1707914
|
[27]
|
Modlin, I.M., Drozdov, I. and Kidd, M. (2013) The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood. PLOS ONE, 8, e63364. https://doi.org/10.1371/journal.pone.0063364
|
[28]
|
Kidd, M., Drozdov, I. and Modlin, I. (2015) Blood and Tissue Neuroendocrine Tumor Gene Cluster Analysis Correlate, Define Hallmarks and Predict Disease Status. Endo-crine-Related Cancer, 22, 561-575.
https://doi.org/10.1530/ERC-15-0092
|
[29]
|
Pavel, M., Jann, H., Prasad, V., et al. (2017) NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology, 104, 170-182.
https://doi.org/10.1159/000446025
|
[30]
|
Modlin, I.M., Kidd, M., Falconi, M., et al. (2021) A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease Outperforms CgA and Has Surgical and Clinical Utility. Annals of Oncology, 32, 1425-1433.
https://doi.org/10.1016/j.annonc.2021.08.1746
|
[31]
|
Modlin, I.M., Kidd, M., Oberg, K., et al. (2021) Early Identifi-cation of Residual Disease after Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signa-ture (NETest). Annals of Surgical Oncology, 28, 7506-7517.
https://doi.org/10.1245/s10434-021-10021-1
|
[32]
|
Van Treijen, M.J.C., Korse, C.M., Van Leeuwaarde, R.S., et al. (2018) Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Valida-tion Study. Frontiers in Endocrinology (Lausanne), 9, Article 740. https://doi.org/10.3389/fendo.2018.00740
|
[33]
|
Rossi, R.E., Elvevi, A., Gallo, C., et al. (2022) Endoscopic Tech-niques for Diagnosis and Treatment of Gastro-Entero- Pancreatic Neuroendocrine Neoplasms: Where We Are. World Journal of Gastroenterology, 28, 3258-3273.
https://doi.org/10.3748/wjg.v28.i26.3258
|
[34]
|
Di Leo, M., Poliani, L., Rahal, D., et al. (2019) Pancreatic Neuro-endocrine Tumours: The Role of Endoscopic Ultrasound Biopsy in Diagnosis and Grading Based on the WHO 2017 Classification. Digestive Diseases, 37, 325-333.
https://doi.org/10.1159/000499172
|
[35]
|
Crino, S.F., Ammendola, S., Meneghetti, A., et al. (2021) Comparison between EUS-Guided Fine-Needle Aspiration Cytology and EUS-Guided Fine-Needle Biopsy Histology for the Evalua-tion of Pancreatic Neuroendocrine Tumors. Pancreatology, 21, 443-450. https://doi.org/10.1016/j.pan.2020.12.015
|
[36]
|
Appelstrand, A., Bergstedt, F., Elf, A.-K., et al. (2022) Endoscopic Ultrasound-Guided Side-Fenestrated Needle Biopsy Sampling Is Sensitive for Pancreatic Neuroendocrine Tumors but Inadequate for Tumor Grading: A Prospective Study. Scientific Reports, 12, Article No. 5971. https://doi.org/10.1038/s41598-022-09923-1
|
[37]
|
Kos-Kudła, B., Foltyn, W., Malczewska, A., et al. (2022) Update of the Diagnostic and Therapeutic Guidelines for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (Recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]. Endokrynologia Polska, 73, 387-454. https://doi.org/10.5603/EP.a2022.0049
|
[38]
|
Malla, S., Kumar, P. and Madhusudhan, K.S. (2021) Radiology of the Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Comprehensive Review. Abdominal Radiology (NY), 46, 919-935.
https://doi.org/10.1007/s00261-020-02773-3
|
[39]
|
Luo, Y., Chen, X., Chen, J., et al. (2020) Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network. Neuroendocrinology, 110, 338-350. https://doi.org/10.1159/000503291
|
[40]
|
Jawlakh, H., Velikyan, I., Welin, S., et al. (2021) 68Ga-DOTATOC-PET/MRI and 11C-5-HTP-PET/MRI Are Superior to 68Ga-DOTATOC-PET/CT for Neuroendocrine Tumour Imaging. Journal of Neuroendocrinology, 33, e12981.
https://doi.org/10.1111/jne.12981
|
[41]
|
王佩佩, 霍力, 刘宇, 等. 无功能胰腺神经内分泌肿瘤18F-FDG PET/CT显像的临床应用价值[J]. 中华核医学与分子影像杂志, 2022, 42(3): 139-143.
|
[42]
|
Dietrich, C.F. and Jenssen, C. (2020) Modern Ultrasound Imaging of Pancreatic Tumors. Ultrasonography, 39, 105-113. https://doi.org/10.14366/usg.19039
|
[43]
|
Choi, S.J., Choi, S.H., Lee, D.Y., et al. (2022) Diagnostic Value of [68Ga]Ga-DOTA-Labeled-Somatostatin Analogue PET/MRI for Detecting Liver Metastasis in Patients with Neuroendo-crine Tumors: A Systematic Review and Meta-Analysis. European Radiology, 32, 4628-4637. https://doi.org/10.1007/s00330-021-08527-z
|
[44]
|
Halfdanarson, T.R., Strosberg, J.R., Tang, L., et al. (2020) The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 49, 863-881. https://doi.org/10.1097/MPA.0000000000001597
|
[45]
|
Zhao, J., Zhao, H. and Chi, Y. (2018) Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. Neuroendocrinology, 106, 318-323. https://doi.org/10.1159/000480402
|
[46]
|
Bongiovanni, A., Liverani, C., Foca, F., et al. (2021) Te-mozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A “Re-al-World” Data Analysis. Neuroendocrinology, 111, 895-906.
https://doi.org/10.1159/000513218
|
[47]
|
Chatzellis, E., Angelousi, A., Daskalakis, K., et al. (2019) Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendo-crine Neoplasms. Neuroendocrinology, 109, 333-345. https://doi.org/10.1159/000500135
|
[48]
|
Bardasi, C., Spallanzani, A., Benatti, S., et al. (2021) Irinotecan-Based Chemotherapy in Extrapulmonary Neuroendocrine Carcinomas: Survival and Safety Data from a Multicentric Italian Experience. Endocrine, 74, 707-713.
https://doi.org/10.1007/s12020-021-02813-y
|
[49]
|
Stueven, A.K., Kayser, A., Wetz, C., et al. (2019) Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International Journal of Molecular Sciences, 20, Article 3049.
https://doi.org/10.3390/ijms20123049
|
[50]
|
Carmona-Bayonas, A., Jiménez-Fonseca, P., Custodio, A., et al. (2017) Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tu-mors. Current Oncology Reports, 19, Article No. 72. https://doi.org/10.1007/s11912-017-0633-2
|
[51]
|
Merola, E., Alonso Gordoa, T., Zhang, P., et al. (2021) Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%? Oncologist, 26, 294-301. https://doi.org/10.1002/onco.13633
|
[52]
|
Pavel, M., O’Toole, D., Costa, F., et al. (2016) ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of In-testinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocri-nology, 103, 172-185. https://doi.org/10.1159/000443167
|
[53]
|
吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020) [J]. 中华外科杂志, 2021, 59(6): 401-421.
|
[54]
|
Yao, J.C., Shah, M.H., Ito, T., et al. (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 364, 514-523. https://doi.org/10.1056/NEJMoa1009290
|
[55]
|
Baudin, E., Berruti, A., Giuliano, M., et al. (2021) First Long-Term Results on Efficacy and Safety of Long-Acting Pasireotide in Combination with Everolimus in Patients with Advanced Carcinoids (NET) of the Lung/Thymus: Phase II LUNA Trial. JCO, 39, 8574. https://doi.org/10.1200/JCO.2021.39.15_suppl.8574
|
[56]
|
Hijioka, S., Morizane, C., Ikeda, M., et al. (2021) Cur-rent Status of Medical Treatment for Gastroenteropancreatic Neuroendocrine Neoplasms and Future Perspectives. Japa-nese Journal of Clinical Oncology, 51, 1185-1196.
https://doi.org/10.1093/jjco/hyab076
|
[57]
|
Dromain, C., Loaiza-Bonilla, A., Mirakhur, B., et al. (2021) Novel Tu-mor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. Oncologist, 26, E632-E638. https://doi.org/10.1002/onco.13669
|
[58]
|
Chang, S.-C., Tsai, C.-Y., Liu, K.-H., et al. (2021) Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor with Liver Metastases: A Case Report and Literature Review. Frontiers in Endocrinology (Lausanne), 12, Article 639967. https://doi.org/10.3389/fendo.2021.639967
|
[59]
|
Couvelard, A., O’Toole, D., Turley, H., et al. (2005) Microvascu-lar Density and Hypoxia-Inducible Factor Pathway in Pancreatic Endocrine Tumours: Negative Correlation of Microvas-cular Density and VEGF Expression with Tumour Progression. British Journal of Cancer, 92, 94-101. https://doi.org/10.1038/sj.bjc.6602245
|
[60]
|
Xu, J., Shen, L., Bai, C., et al. (2020) Surufatinib in Advanced Pancre-atic Neuroendocrine Tumours (SANET-p): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lan-cet Oncology, 21, 1489-1499.
https://doi.org/10.1016/S1470-2045(20)30493-9
|
[61]
|
Capdevila, J., Fazio, N., Lopez Lopez, C., et al. (2019) Final results of the TALENT Trial (GETNE1509): A Prospective Multicohort Phase II Study of Lenvatinib in Patients (pts) with G1/G2 Advanced Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors (NETs). JCO, 37, 4106.
https://doi.org/10.1200/JCO.2019.37.15_suppl.4106
|
[62]
|
Fazio, N., Kulke, M., Rosbrook, B., et al. (2021) Up-dated Efficacy and Safety Outcomes for Patients with Well- Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib. Targeted Oncology, 16, 27-35.
https://doi.org/10.1007/s11523-020-00784-0
|
[63]
|
Lu, M., Zhang, P., Zhang, Y., et al. (2020) Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clinical Cancer Research, 26, 2337-2345.
https://doi.org/10.1158/1078-0432.CCR-19-4000
|
[64]
|
Strosberg, J., Mizuno, N., Doi, T., et al. (2020) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results from the Phase II KEYNOTE-158 Study. Clinical Cancer Research, 26, 2124-2130.
https://doi.org/10.1158/1078-0432.CCR-19-3014
|
[65]
|
Klein, O., Kee, D., Markman, B., et al. (2019) A Phase II Clinical Trial of Ipilimumab/Nivolumab Combination Immunotherapy in Patients with Rare Upper Gastrointestinal, Neu-roendocrine, and Gynecological Malignancies. JCO, 37, 2570. https://doi.org/10.1200/JCO.2019.37.15_suppl.2570
|
[66]
|
Shen, L., Yu, X., Lu, M., et al. (2021) Surufatinib in Combination with Toripalimab in Patients with Advanced Neuroendocrine Carcinoma: Results from a Multicenter, Open-Label, Single-Arm, Phase II Trial. JCO, 39, e16199.
https://doi.org/10.1200/JCO.2021.39.15_suppl.e16199
|
[67]
|
Ito, T., Masui, T., Komoto, I., et al. (2021) JNETS Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms: Diagnosis, Treatment, and Fol-low-Up: A Synopsis. Journal of Gastroenterology, 56, 1033-1044.
https://doi.org/10.1007/s00535-021-01827-7
|
[68]
|
Strosberg, J.R., Caplin, M.E., Kunz, P.L., et al. (2021) Final Overall Survival in the Phase 3 NETTER-1 Study of Lutetium-177-DOTATATE in Patients with Midgut Neuroendo-crine Tumors. JCO, 39, 4112.
https://doi.org/10.1200/JCO.2021.39.15_suppl.4112
|
[69]
|
Clement, D., Navalkissoor, S., Srirajaskanthan, R., et al. (2021) Efficacy and Safety of 177Lu-DOTATATE in Patients (pts) with Advanced Pancreatic Neuroendocrine Tumors (pNETs): Data from the NETTER-R International, Retrospective Registry. JCO, 39, 4116. https://doi.org/10.1200/JCO.2021.39.15_suppl.4116
|
[70]
|
Nicolas, G.P., Ansquer, C., Lenzo, N.P., et al. (2020) 1160O An International Open-Label Study on Safety and Efficacy of 177Lu-Satoreotide Tetraxetan in Somatostatin Re-ceptor Positive Neuroendocrine Tumours (NETs): An Interim Analysis. Annals of Oncology, 31, S771. https://doi.org/10.1016/j.annonc.2020.08.1373
|
[71]
|
Fross-Baron, K., Garske-Roman, U., Welin, S., et al. (2021) Lu-177-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. Neuroendocrinology, 111, 330-343. https://doi.org/10.1159/000506746
|